Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

Antonio Scalfari, Anneke Neuhaus, Alexandra Degenhardt et al. · Brain · 2010 · 718 citations · Full text

Medicine, Neurology, Disability Management +14

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P ₁ ) modulation

Ji Woong Choi, Shannon E. Gardell, Deron R. Herr et al. · Proceedings of the National Academy of Sciences · 2010 · 578 citations · Full text

Medicine, Neurobiology, Neurology +17

Differential Regulation of Sinusoidal and Canalicular Hepatic Drug Transporter Expression by Xenobiotics Activating Drug-Sensing Receptors in Primary Human Hepatocytes

Émilie Jigorel, Marc Le Vée, Claire Boursier-Neyret et al. · Drug Metabolism and Disposition · 2006 · 305 citations

Pharmacy, Pharmacology, Toxicology +16

The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rate

P Gergely, Barbara Nuesslein‐Hildesheim, Danilo Guerini et al. · British Journal of Pharmacology · 2012 · 304 citations · Full text

Life Sciences, Immunology, Pharmacology +15